AstraZeneca PLC (AZN)


NYSE - NYSE Real Time Price. Currency in USD
33.82+0.21 (+0.62%)
At close: 4:02 PM EDT
People also watch:
GSKNVSSNYLLYBMY
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Open33.99
Prev Close33.61
Bid31.00 x 1000
Ask34.00 x 1000
Day's Range33.73 - 34.09
52wk Range26.97 - 35.04
1y Target EstN/A
Market Cap84.4B
P/E Ratio (ttm)38.65
Beta0.58
Volume7,443,628
Avg Vol (3m)5,981,737
Dividend & Yield0.90 (2.68%)
Earnings DateN/A
Trade prices are not sourced from all markets
  • American City Business Journals9 hours ago

    Big Pharma takes big lease in South S.F. to consolidate California operations

    Drug developer AstraZeneca PLC will bring more than 350 California employees together in the massive Cove at Oyster Point development in South San Francisco, the company said Tuesday. It comes as Big Pharma players, including Merck & Co. Inc., scout local sites in an effort to cozy up to hot, young Bay Area drug developers . The Cove, now in the second phase of construction by HCP Inc. at Highway 101 and Oyster Point Boulevard, already has landed high-profile biotech startups, such as neurodegenerative drug developer Denali Therapeutics Inc. and cancer drug maker CytomX Therapeutics Inc. But AstraZeneca (AZN) could dwarf those companies with its expected fourth-quarter 2017 move-in.

  • Reuters22 hours ago

    Zuckerberg initiative poaches AstraZeneca board member

    The $3 billion health initiative set up by Facebook co-founder Mark Zuckerberg and his wife Priscilla Chan has hired one of AstraZeneca's non-executive directors to head up its science drive. The British drugmaker said on Wednesday that Cornelia Bargmann would step down from its board next month to take up a new role as president of Chan Zuckerberg Science, part of the Chan Zuckerberg Initiative. Leif Johansson, AstraZeneca's chairman, said the board was sorry to see her leave but understood Bargmann's decision to focus on the new assignment.

  • TheStreet.com2 days ago

    Bristol, Nektar Research Pact Aims to Boost Efficacy of Cancer Immunotherapy

    A series of clinical trials will test the combination of Bristol-Myers Squibb's Opdivo with Nektar's NKTR-214 in multiple tumor types.